Erudio Healtherudio.com
Sponsor
Boehringer Ingelheim trials: what clinicians said in public
An HCP commentary report on 1 clinical trial sponsored by Boehringer Ingelheim: DAREON-NEC-1. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 10 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (Boehringer Ingelheim). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| DAREON-NEC-1 NCT07544654 · Boehringer Ingelheim | first-line DLL3-positive advanced extrapulmonary neuroendocrine carcinomas | Phase 3 | 58 | 6 | Focused | Nov 15, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| Beamion LUNG-1 NCT04886804 · Boehringer Ingelheim DeepView → | advanced or metastatic solid tumors with HER2 aberrations | Phase 1 | Deep | View | |||
| DAREON-7 NCT06132113 · Boehringer Ingelheim DeepView → | first-line advanced neuroendocrine carcinomas | Phase 1 | Deep | View | |||
| Brightline-1 NCT05218499 · Boehringer Ingelheim DeepView → | first-line advanced dedifferentiated liposarcoma | Phase 2/Phase 3 | Deep | View | |||
| Beamion LUNG-2 NCT06151574 · Boehringer Ingelheim StandardView → | Not given | Phase 3 | Standard | View | |||
| LUME-Meso NCT01907100 · Boehringer Ingelheim FocusedView → | unresectable malignant pleural mesothelioma | Phase 2/Phase 3 | Focused | View | |||
| Beamion LUNG-3 NCT07195695 · Boehringer Ingelheim FocusedView → | Not given | Phase 3 | Focused | View | |||
| NCT04429087 NCT04429087 · Boehringer Ingelheim FocusedView → | Not given | Phase 1 | Focused | View | |||
| NCT05879978 NCT05879978 · Boehringer Ingelheim FocusedView → | DLL3-positive small cell lung cancer and neuroendocrine neoplasms | Phase 1 | Focused | View | |||
| NCT03449381 NCT03449381 · Boehringer Ingelheim FocusedView → | Not given | Phase 1 | Focused | View | |||
| DAREON-9 NCT05990738 · Boehringer Ingelheim FocusedView → | relapsed/refractory small cell lung cancer | Phase 1 | Focused | View | |||